These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 30521987)
41. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity. Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368 [TBL] [Abstract][Full Text] [Related]
42. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727 [TBL] [Abstract][Full Text] [Related]
43. PALB2 sequence variants in young South African breast cancer patients. Sluiter M; Mew S; van Rensburg EJ Fam Cancer; 2009; 8(4):347-53. PubMed ID: 19333784 [TBL] [Abstract][Full Text] [Related]
44. Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer. Hellebrand H; Sutter C; Honisch E; Gross E; Wappenschmidt B; Schem C; Deissler H; Ditsch N; Gress V; Kiechle M; Bartram CR; Schmutzler RK; Niederacher D; Arnold N; Meindl A Hum Mutat; 2011 Jun; 32(6):E2176-88. PubMed ID: 21618343 [TBL] [Abstract][Full Text] [Related]
45. Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2. Catucci I; Casadei S; Ding YC; Volorio S; Ficarazzi F; Falanga A; Marchetti M; Tondini C; Franchi M; Adamson A; Mandell J; Walsh T; Olopade OI; Manoukian S; Radice P; Ricker C; Weitzel J; King MC; Peterlongo P; Neuhausen SL Breast Cancer Res Treat; 2016 Nov; 160(1):121-129. PubMed ID: 27624329 [TBL] [Abstract][Full Text] [Related]
46. [What attitude to women at high risk of breast cancer?]. Livon D; Moretta J; Noguès C Presse Med; 2019 Oct; 48(10):1092-1100. PubMed ID: 31706893 [TBL] [Abstract][Full Text] [Related]
47. Mutation screening of PALB2 in clinically ascertained families from the Breast Cancer Family Registry. Nguyen-Dumont T; Hammet F; Mahmoodi M; Tsimiklis H; Teo ZL; Li R; Pope BJ; Terry MB; Buys SS; Daly M; Hopper JL; Winship I; Goldgar DE; Park DJ; Southey MC Breast Cancer Res Treat; 2015 Jan; 149(2):547-54. PubMed ID: 25575445 [TBL] [Abstract][Full Text] [Related]
48. The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families? Eliade M; Skrzypski J; Baurand A; Jacquot C; Bertolone G; Loustalot C; Coutant C; Guy F; Fumoleau P; Duffourd Y; Arnould L; Delignette A; Padéano MM; Lepage C; Raichon-Patru G; Boudrant A; Bône-Lépinoy MC; Villing AL; Charpin A; Peignaux K; Chevrier S; Vegran F; Ghiringhelli F; Boidot R; Sevenet N; Lizard S; Faivre L Oncotarget; 2017 Jan; 8(2):1957-1971. PubMed ID: 27779110 [TBL] [Abstract][Full Text] [Related]
50. Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene. Silvestri V; Zelli V; Valentini V; Rizzolo P; Navazio AS; Coppa A; Agata S; Oliani C; Barana D; Castrignanò T; Viel A; Russo A; Tibiletti MG; Zanna I; Masala G; Cortesi L; Manoukian S; Azzollini J; Peissel B; Bonanni B; Peterlongo P; Radice P; Palli D; Giannini G; Chillemi G; Montagna M; Ottini L Cancer; 2017 Jan; 123(2):210-218. PubMed ID: 27648926 [TBL] [Abstract][Full Text] [Related]
51. Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer. Blanco A; de la Hoya M; Balmaña J; Ramón y Cajal T; Teulé A; Miramar MD; Esteban E; Infante M; Benítez J; Torres A; Tejada MI; Brunet J; Graña B; Balbín M; Pérez-Segura P; Osorio A; Velasco EA; Chirivella I; Calvo MT; Feliubadaló L; Lasa A; Díez O; Carracedo A; Caldés T; Vega A Breast Cancer Res Treat; 2012 Feb; 132(1):307-15. PubMed ID: 22052327 [TBL] [Abstract][Full Text] [Related]
52. A high frequency of PALB2 mutations in Jamaican patients with breast cancer. Lerner-Ellis J; Donenberg T; Ahmed H; George S; Wharfe G; Chin S; Lowe D; Royer R; Zhang S; Narod S; Hurley J; Akbari MR Breast Cancer Res Treat; 2017 Apr; 162(3):591-596. PubMed ID: 28194609 [TBL] [Abstract][Full Text] [Related]
54. Rare germline mutations in PALB2 and breast cancer risk: a population-based study. Tischkowitz M; Capanu M; Sabbaghian N; Li L; Liang X; Vallée MP; Tavtigian SV; Concannon P; Foulkes WD; Bernstein L; ; Bernstein JL; Begg CB Hum Mutat; 2012 Apr; 33(4):674-80. PubMed ID: 22241545 [TBL] [Abstract][Full Text] [Related]
55. Germline mutations in Chinese ovarian cancer with or without breast cancer. Kwong A; Ho CYS; Shin VY; Au CH; Luk WP; Fung LH; Chan TL; Chan KKL; Ngan HYS; Ma ESK Mol Genet Genomic Med; 2022 Jul; 10(7):e1940. PubMed ID: 35608067 [TBL] [Abstract][Full Text] [Related]
56. Prevalence of PALB2 mutations in breast cancer patients in multi-ethnic Asian population in Malaysia and Singapore. Phuah SY; Lee SY; Kang P; Kang IN; Yoon SY; Thong MK; Hartman M; Sng JH; Yip CH; Taib NA; Teo SH PLoS One; 2013; 8(8):e73638. PubMed ID: 23977390 [TBL] [Abstract][Full Text] [Related]
57. Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA. Grellety T; Peyraud F; Sevenet N; Tredan O; Dohollou N; Barouk-Simonet E; Kind M; Longy M; Blay JY; Italiano A Ann Oncol; 2020 Jun; 31(6):822-823. PubMed ID: 32194151 [No Abstract] [Full Text] [Related]
58. Missense PALB2 germline variant disrupts nuclear localization of PALB2 in a patient with breast cancer. Toh MR; Low CE; Chong ST; Chan SH; Ishak NDB; Courtney E; Kolinjivadi AM; Rodrigue A; Masson JY; Ngeow J Fam Cancer; 2020 Apr; 19(2):123-131. PubMed ID: 32048105 [TBL] [Abstract][Full Text] [Related]
59. Hereditary truncating mutations of DNA repair and other genes in BRCA1/BRCA2/PALB2-negatively tested breast cancer patients. Lhota F; Zemankova P; Kleiblova P; Soukupova J; Vocka M; Stranecky V; Janatova M; Hartmannova H; Hodanova K; Kmoch S; Kleibl Z Clin Genet; 2016 Oct; 90(4):324-33. PubMed ID: 26822949 [TBL] [Abstract][Full Text] [Related]
60. Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer. Wong-Brown MW; Avery-Kiejda KA; Bowden NA; Scott RJ Int J Cancer; 2014 Jan; 134(2):301-5. PubMed ID: 23824750 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]